Clinical evaluation of Rho(D) immune globulin (human) in Canada.
-During 1966, clinical trials were conducted in three Canadian centres to determine the safety and efficacy of Rh(0)(D) immune globulin (human) in preventing isoimmunization by the Rh(0)(D) antigen in Rh-negative women delivering ABO-compatible Rh-positive infants.The candidates were randomly divided into control and treated groups; the treated mothers received an intramuscular injection of 300 mug. of anti-Rh(0)(D) within 72 hours of delivery. Follow-up antibody screening tests were conducted on the sera of all patients six to nine months post partum.Of the 175 control patients, 11 or 6.2% became actively immunized to the Rh antigen, whereas complete protection against maternal Rh immunization was observed in the 191 treated patients.
D000017:ABO Blood-Group System; D000906:Antibodies / Q000032:analysis; D036861:Delivery, Obstetric; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007114:Immunization; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins / Q000008:administration & dosage*
D000017:ABO Blood-Group System; D000906:Antibodies; D012204:Rh-Hr Blood-Group System; D005719:gamma-Globulins